Brought to you by 
Biofrontera and Kiadis agree to merge; withdrawn
19 Apr 2021
Executive Summary
Biofrontera Pharmaceuticals GMBH (drug discovery for nervous system disorders) and Kiadis BV (identifies biologically active compounds) have agreed on a merger of equals. They plan to continue to operate in their respective locations as wholly owned subsidiaries of a new holding company, Aliga Pharmaceuticals AG.
Deal Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- Bioinformatics
- Genomics-Proteomics
-
Molecular Diversity
- Natural Products
-
Drug Discovery Tools
Deal Status
- Withdrawn
Deal Type
-
Acquisition
- Full Acquisition
- Intra-Biotech Deal
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Biofrontera and Kiadis agree to merge; withdrawn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice